Institute for International Research

Chairpersons Opening Remarks

Shashank Upadhye, Esq.
Vice President - Global Head of Intellectual Property
APOTEX, INC.

SENATORIAL ADDRESS: Removing Hurdles that Slow Affordable Generics from Coming to Market

Senator Debbie A. Stabenow
US SENATE

CONGRESSIONAL ADDRESS: The Future of Biogenerics and Other Measures to Reduce Healthcare Costs

Representative Frank Pallone, Jr,
MEMBER OF CONGRESS, UNITED STATES, 6TH DISTRICT OF NEW JERSEY

FTC ADDRESS: Federal Trade Commission Actions Involving Generic Drugs

Phil Eisenstat
Senior Attorney
FEDERAL TRADE COMMISSION 

Examine the Past, Present and Possible Future of Proving Equivalency for Topical and Locally Acting Oral Generics

Panelists:
David L. Rosen
Partner
FOLEY & LARDNER LLP

Charles E. DiLiberti
Vice President, Scientific Affairs
BARR LABS

Patent Term Extension: 35 U.S.C. § 156(f): What is the approved product?

Michelle A. Sherwood
Counsel
BRINKS HOFER GILSON & LIONE

Trends in New Pharmaceutical Patent Claim Strategies

Shashank Upadhye, Esq.
Vice President - Global Head of Intellectual Property
APOTEX, INC.

FDA Perspective on International Trends

Steven Wolfgang
Compliance Officer
FDA/CDER

Patient, Prescriber and Plan Sponsor - A Multifaceted Approach to Increasing Generic Utilization - An Insurer's Perspective

Ed Pezalla, MD, MPH
National Medical Director, Pharmacy Management
AETNA PHARMACY MANAGEMENT

Conference Concludes